Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2434 Target Snapshot

C-X-C chemokine receptor type 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,337Compounds
238Assays
2Approved Drugs
3,391.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

C-X-C chemokine receptor type 2 shows late clinical disease relevance led by type 1 diabetes mellitus. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P25025. Start with type 1 diabetes mellitus, then reuse UniProt P25025 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with type 1 diabetes mellitus, then reuse UniProt P25025 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
type 1 diabetes mellitus

C-X-C chemokine receptor type 2 shows late clinical disease relevance led by type 1 diabetes mellitus. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with type 1 diabetes mellitus because it currently carries late clinical support. Linked drugs include LADARIXIN, REPARIXIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats C-X-C chemokine receptor type 2 as ChEMBL target CHEMBL2434, mapped to UniProt P25025. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
C-X-C chemokine receptor type 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2434
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P25025
C-X-C chemokine receptor type 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether C-X-C chemokine receptor type 2 is the right protein anchor across sources, using UniProt P25025 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why type 1 diabetes mellitus is currently framed as late clinical support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameC-X-C chemokine receptor type 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP25025
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelC-X-C chemokine receptor type 2
UniProt AccessionP25025
Component TypeProtein
Sequence Length360 aa

C-X-C chemokine receptor type 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as C-X-C chemokine receptor type 2, mapped to UniProt P25025. Sequence length is 360 aa.

Mapped IDP25025
Review nameC-X-C chemokine receptor type 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

C-X-C chemokine receptor type 2 shows late clinical disease relevance led by type 1 diabetes mellitus. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
type 1 diabetes mellitus
2 linked drugs · 2 direct · 2 efficacy
Linked drugLADARIXIN
Linked drugREPARIXIN
Late clinical Phase III
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugREPARIXIN
Late clinical Phase III
pneumonia
1 linked drug · 1 direct · 1 efficacy
Linked drugREPARIXIN
Late clinical Phase III
viral pneumonia
1 linked drug · 1 direct · 1 efficacy
Linked drugREPARIXIN
Clinical signal Phase II
chronic obstructive pulmonary disease
3 linked drugs · 3 direct · 3 efficacy
Linked drugDANIRIXIN
Linked drugELUBRIXIN
Linked drugNAVARIXIN
Clinical signal Phase II
adult acute respiratory distress syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugREPARIXIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with type 1 diabetes mellitus because it currently carries late clinical support. Linked drugs include LADARIXIN, REPARIXIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasetype 1 diabetes mellitus
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
2
Phase III
10
Phase II
Assay Mix

Activity Type Distribution

IC502,282.0
KI1,076.0
EC502.0
KD31.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL218115 10.31 Kd 0.049 Preclinical
CHEMBL216981 10.31 IC50 0.049 Clinical
CHEMBL216981 10.31 Kd 0.049 Clinical
CHEMBL4442431 10.0 IC50 0.1 Preclinical
CHEMBL577075 9.92 IC50 0.12 Preclinical
CHEMBL4066904 9.8 IC50 0.1585 Preclinical
CHEMBL4082136 9.7 IC50 0.1995 Preclinical
CHEMBL4098864 9.7 IC50 0.1995 Preclinical
CHEMBL4128926 9.62 IC50 0.24 Preclinical
CHEMBL4562140 9.61 Ki 0.2455 Preclinical
Distribution

pChEMBL Value Distribution

111
5.0
153
5.5
172
6.0
213
6.5
176
7.0
179
7.5
210
8.0
60
8.5
49
9.0
13
9.5
pChEMBL
Assay Landscape

Assay Landscape

238
Total Assays
981
Tested Compounds
2
Assay Types
Binding — 185 assays, 981 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 95 249 7.4
cell-based format 72 616 6.9
cell membrane format 11 19 7.8
assay format 7 97 7.6
Functional — 53 assays, 293 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 31 265 6.5
assay format 17 21 7.8
single protein format 5 7 6.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine